{
    "clinical_study": {
        "@rank": "43392", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1", 
                "arm_group_type": "Experimental", 
                "description": "Baclofen low dose"
            }, 
            {
                "arm_group_label": "Arm 2", 
                "arm_group_type": "Experimental", 
                "description": "Baclofen high dose"
            }, 
            {
                "arm_group_label": "Arm 3", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "To explore the effectiveness and biobehavioural basis of baclofen in improving treatment\n      outcomes for alcohol dependence in people with alcoholic cirrhosis in a double-blind\n      randomised placebo-controlled trial."
        }, 
        "brief_title": "Baclofen in the Treatment of Alcoholic Liver Disease", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Alcoholic Liver Disease", 
        "condition_browse": {
            "mesh_term": [
                "Liver Diseases", 
                "Liver Diseases, Alcoholic"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a double-blind randomised placebo-controlled study investigating the efficacy of\n      baclofen for the treatment of alcohol dependence in patients with alcoholic liver disease.\n      Medications will be given for 12 weeks, with a further 6 months follow-up. Both male and\n      female participants will be recruited to this study. Trial patients will be randomised to\n      one of three treatment groups: (1) baclofen 30mg/day (10 mg t.i.d), (2) baclofen 75mg/day\n      (25 mg t.i.d) or (3) Placebo (3 matched tabs/day)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  ALD, defined as the presence of symptoms and/or signs referable to liver disease with\n             or without cirrhosis, in which alcohol use is considered to play a major aetiological\n             role. Alcohol use will have exceeded an average of 60g/day in women and 80g/day in\n             men for >10 years.\n\n          -  Alcohol dependence according to the ICD-10 criteria\n\n          -  Adequate cognition and English language skills to give valid consent and complete\n             research interviews\n\n          -  Willingness to give written informed consent\n\n          -  Abstinence from alcohol for between 3 and 21 days\n\n          -  Resolution of any clinically evident alcohol withdrawal (CIWA-AR)\n\n        Exclusion Criteria:\n\n          -  Active major psychological disorder associated with psychosis or significant suicide\n             risk\n\n          -  Pregnancy or lactation\n\n          -  Concurrent use of any psychotropic medication other than antidepressants\n\n          -  Substance use other than nicotine if unstable\n\n          -  Clinical evidence of persisting hepatic encephalopathy\n\n          -  Pending incarceration\n\n          -  Lack of stable housing\n\n          -  Active peptic ulcers\n\n          -  Unstable diabetes mellitus"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "180", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01711125", 
            "org_study_id": "X11-0154"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm 1", 
                "description": "30mg/day 10 mg t.i.d", 
                "intervention_name": "Baclofen 30mg/day", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm 2", 
                "description": "75mg/day 25 mg t.i.d", 
                "intervention_name": "Baclofen 75mg/day", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm 3", 
                "description": "Placebo 3 matched tabs/day", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Baclofen"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 8, 2013", 
        "location": {
            "contact": {
                "email": "kirsten.morley@sydney.edu.au", 
                "last_name": "Kirsten C Morley, PhD", 
                "phone": "+61295153636"
            }, 
            "contact_backup": {
                "email": "sydneyalcoholtreatmentgroup@gmail.com", 
                "last_name": "Central Intake", 
                "phone": "95157611"
            }, 
            "facility": {
                "address": {
                    "city": "Sydney", 
                    "country": "Australia", 
                    "state": "New South Wales", 
                    "zip": "2050"
                }, 
                "name": "Drug Health Services, Royal Prince Alfred Hospital"
            }, 
            "investigator": {
                "last_name": "Paul Haber, MBBS", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Australia"
        }, 
        "number_of_arms": "3", 
        "official_title": "Exploring the Efficacy and Biobehavioural Basis of Baclofen in the Treatment of Alcoholic Liver Disease", 
        "overall_contact": {
            "email": "kirsten.morley@sydney.edu.au", 
            "last_name": "Kirsten Morley, PhD", 
            "phone": "+61295153636"
        }, 
        "overall_official": [
            {
                "affiliation": "Sydney Local Health District", 
                "last_name": "Paul S Haber, MBBS", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Macquarie University", 
                "last_name": "Andrew Baillie, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "as measured by the number of days abstinent, number of heavy drinking days, time to relapse, time to lapse and number of drinks per drinking day", 
            "measure": "alcohol consumption", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01711125"
        }, 
        "responsible_party": {
            "investigator_affiliation": "South West Sydney Local Health District", 
            "investigator_full_name": "Professor Paul Haber", 
            "investigator_title": "Medical Director", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "clinical markers of liver injury", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "incidence of hepatic side effects", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "craving for alcohol", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "early termination due to side effects", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "South West Sydney Local Health District", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Health and Medical Research Council, Australia", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Sydney", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "South West Sydney Local Health District", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}